Chemkart India (CHEMKART) Q4 FY26's Profit Growth Stalls Despite a 24% Revenue Jump
The chemical distributor posted strong Q4 sales but saw profits squeezed by higher costs, highlighting the margin pressure in its core trading business.
Chemkart India's Q4 revenue surged 24% year-on-year to ₹112 crore, yet profit growth lagged at 11%. The gap points to significant margin pressure from rising input costs, a trend that defined its full-year performance.
For a chemical distributor like Chemkart India, growth is a story of volume and pricing. The fourth quarter delivered on the top line, with revenue surging 24.4% year-on-year to ₹112 crore, but the profit story was far more muted. Net profit grew just 11.1% to ₹10 crore, revealing a margin squeeze that has become the defining theme of its financial year.
The numbers show a clear divergence. While quarterly sales climbed 8.7% sequentially, profit stayed flat at ₹10 crore. For the full year FY26, revenue grew 5.7% to ₹214.83 crore, but profit fell sharply by 19.9% to ₹19.66 crore. The net profit margin for the quarter stood at 8.9%, down 110 basis points from the same period last year.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ4 FY26 | Same quarter LYQ4 FY25 |
|---|---|---|
| Revenue (₹ Cr) | 112.0YoY +24% | 90.0 |
| Profit (₹ Cr) | 10.0YoY +11% | 9.0 |
| Net Profit Margin (%) | 8.9YoY -11% | 10.0 |
Where the sales gain was lost
Research from Multibagg.ai points to higher expenses as the primary culprit for the margin decline. The cost of purchased traded goods, a major expense line, increased significantly. This suggests that while Chemkart successfully moved more product, the cost of acquiring those ingredients rose faster than it could pass on to customers. The company's model as a B2B trader of nutraceutical ingredients leaves it exposed to global commodity price swings and supply chain volatility.
A year of transition under cost pressure
The full-year profit decline of nearly 20% underscores that the Q4 squeeze was not an isolated event. According to a report by Scanx.trade, a surge in the cost of materials consumed, which rose over 53%, severely compressed earnings. This pressure is visible in the company's cash flow, with operating cash flow turning negative at ₹-3 crore for FY26, as per data from Newboard.in. Money is increasingly tied up in working capital, with the cash conversion cycle stretching to 119 days.
The manufacturing pivot as a margin solution
Management's strategic response is a pivot from pure trading to manufacturing. The company is constructing a nutraceutical CDMO facility in a JNPT Special Economic Zone through its subsidiary, Easy Raw Materials. As noted in an investor presentation covered by Arthneeti.com, this move aims to capture more value through formulation and packaging. The goal is to build an integrated platform that relies less on volatile trading margins and more on proprietary, higher-margin production.
Key Points
- Q4 FY26 revenue grew 24.4% year-on-year, but profit growth of 11.1% lagged significantly, compressing the net profit margin by 110 basis points.
- Full-year FY26 profit fell 19.9% despite a 5.7% rise in revenue, driven by a sharp increase in input costs, particularly purchased goods.
- Operating cash flow was negative for the year, and the cash conversion cycle extended to 119 days, indicating tighter working capital management.
- The company is investing in a new SEZ-based manufacturing facility to transition from low-margin trading to integrated production and improve long-term profitability.
Hexa Perspective
Chemkart's quarter captures a trader's dilemma: strong sales volumes are no longer enough to guarantee profit growth when input costs are rising. The 110 bps margin decline on a 24% sales increase is a stark illustration of this pressure. The company's high return on equity of 15.15% shows an efficient use of capital, but the negative cash conversion suggests that efficiency is not yet translating into cash.
The path forward hinges on the success of its manufacturing pivot. Until the new facility is operational, Chemkart remains largely at the mercy of global ingredient prices and its ability to manage working capital. Investors are effectively funding this transition now, betting that future margins from manufacturing will justify the current period of squeezed profitability and cash outflow.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.